Piracetam
Nootropil, Memotropil, Pirasmart — the 1964 parent of the racetam class
Piracetam (Nootropil, Memotropil, Pirasmart — the 1964 parent of the racetam class) is a cognitive & mood research compound. The molecule every other racetam on this site is a derivative of, and the one with no identified receptor after sixty years. The mechanism on offer is physico-chemical rather than pharmacological: an interaction with the polar head groups of the phospholipid bilayer that alters membrane fluidity, reported as larger in aged brain membranes than young ones, with a mitochondrial extension — raised membrane potential and ATP production — proposed on top of it. Its own structural descendant, levetiracetam, does have a named target: the synaptic vesicle protein SV2A.
Piracetam quick facts
| Route | Oral |
| Frequency | 2-3x Daily |
| Half-life | ~5 hrs (European product information; there is no US label) |
| Forms | Oral |
| Evidence level | Human trials — positive in cortical myoclonus; the Cochrane review for dementia and cognitive impairment does not support that use. Not approved in the US. |
The parent of the class, and its clearest human result is not a cognition result. A 21-patient double-blind placebo-controlled crossover in cortical myoclonus at 2.4-16.8 grams daily saw 10 of 21 patients need rescuing from the placebo arm and none from the drug arm, with a median 22% improvement in total rating score. The Cochrane review of piracetam for dementia or cognitive impairment does not support that indication and has not been updated since 2001. Note the dose gap before drawing conclusions: the 800mg and 1200mg tablets on sale are a fraction of the only range with a controlled result behind it.
How Piracetam works
The molecule every other racetam on this site is a derivative of, and the one with no identified receptor after sixty years. The mechanism on offer is physico-chemical rather than pharmacological: an interaction with the polar head groups of the phospholipid bilayer that alters membrane fluidity, reported as larger in aged brain membranes than young ones, with a mitochondrial extension — raised membrane potential and ATP production — proposed on top of it. Its own structural descendant, levetiracetam, does have a named target: the synaptic vesicle protein SV2A.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Piracetam
Buy Piracetam at RUPharma →The evidence for Piracetam
Graded by what exists behind each claim.
✅ Clinically validated
- The clearest controlled result is not a cognition result. A 21-patient double-blind placebo-controlled crossover in disabling myoclonus, almost all of cortical origin, at 2.4 to 16.8 grams daily: 10 of 21 had to be rescued from the placebo arm and none from the drug arm, with a median 22% improvement in total rating score (Brown 1993, Mov Disord).
- The Cochrane review of piracetam for dementia or cognitive impairment does not support that use (Flicker & Grimley Evans 2001) — and it has not been updated since.
- Not approved in the US. There is no DailyMed prescribing information for it, so there is no regulator-reviewed adverse-event table to quote. That is an absent safety record, not a clean one.
📊 Correlative data
- Decades of European clinical use at gram doses, and a much larger volume of community use at 800-1600 mg — which is a fraction of the only range with a controlled result behind it. The dose gap is the single biggest reason community reports and trial results disagree.
- Market surveillance by 12 official medicines control laboratories across Europe and Australia found most nootropic samples came from the illegal market, with prescription drugs present in pharmacological quantities (Vanhee 2025).
🧪 Theoretical / extrapolated
- Sixty years and no identified receptor. The mechanism on offer is physico-chemical: interaction with phospholipid head groups altering membrane fluidity, reported as larger in aged brain membranes than young ones (Muller 1999), with a mitochondrial extension — raised membrane potential and ATP production — layered on top (Leuner 2010).
- Its own descendant has the target it lacks. Levetiracetam is piracetam plus an ethyl group from the same company, and its label names a saturable, stereoselective binding site identified as SV2A. Nobody has run that assay on the parent.
- The mechanism's own prediction cuts against retail use: a membrane effect that is larger in aged membranes should do less in a young healthy brain. Its advocates say so explicitly.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Piracetam actually does
Sixty years on, this molecule still has no identified receptor, and the way to say that usefully is to put its own descendant next to it. Levetiracetam is piracetam with an ethyl group on the acetamide carbon, made by the same company, and its FDA label names a target: “A saturable and stereoselective neuronal binding site in rat brain tissue has been described … this binding site is the synaptic vesicle protein SV2A” Keppra label 2026. Contreras-Garcia 2022 traces that binding from the molecule up to the circuit. The parent has no equivalent sentence anywhere. One ethyl group separates a drug with a named protein target from a drug with a physico-chemical hypothesis, and no page in this market puts the two documents side by side.
What the hypothesis actually claims, stated precisely enough to be wrong. Muller 1999 argues that piracetam does not bind a protein at all: it interacts with the polar head groups of the phospholipid bilayer and alters membrane fluidity. The distinctive part is the conditionality. The effect is reported as more pronounced in membranes from aged brains than young ones, and specifically relevant to membranes from Alzheimer brains. From the same argument come the vascular claims — improved erythrocyte deformability, normalized hyperactive platelet aggregation — because a red cell squeezing through a capillary is a membrane mechanics problem before it is a pharmacology problem.
The mitochondrial extension, and where it came from. Leuner 2010 follows the fluidity finding into the mitochondrial membrane and reports raised mitochondrial membrane potential, increased ATP production and reduced sensitivity to apoptosis across cell and animal models of aging and Alzheimer disease, with elevated neuronal plasticity as the downstream consequence. Note the shape of that chain: a physical property of a lipid bilayer, then an organelle function, then a network property. Every step is plausible and every step is a level of abstraction further from anything measured in a person.
The prediction the mechanism makes, which is the reason it is worth taking seriously. A non-specific membrane effect that is larger in aged membranes predicts, unavoidably, that the drug does less in a young healthy brain than in an old impaired one. Muller 1999 says exactly this: effects are always much more pronounced when function is impaired. That is a falsifiable claim, it cuts directly against the retail use of the compound, and it comes from the mechanism's own advocates.
Cell, rodent, human — and where it stops
The cell and membrane rung is where nearly all of this compound's mechanism lives Muller 1999 Leuner 2010. Membrane fluidity, mitochondrial membrane potential and ATP synthesis in cell and animal models of aging. No receptor occupancy, no transporter, no enzyme inhibition constant, because none has been established.
The human rung that worked is not a cognition trial. Brown 1993 enrolled 21 patients with disabling myoclonus — all but one with electrophysiological evidence of cortical origin — into a placebo-controlled double-blind crossover of piracetam at 2.4 to 16.8 grams daily, 14 days per arm, mostly added on top of existing antimyoclonic drugs. The result is unusually clean for this literature: 10 of the 21 had to be rescued from the placebo phase because their myoclonus became severe and intolerable, and none required rescue from the piracetam phase. Motor, writing, functional disability, global assessment and visual analog scores all improved significantly, and the total rating score improved by a median of 22%. That is a real drug doing a real thing.
The human rung it is actually sold for did not work. Flicker 2001 is the Cochrane review of piracetam for dementia or cognitive impairment, and its conclusion does not support the use of piracetam for that indication. It has not been updated since. So the strongest positive human evidence for this compound concerns a movement disorder at gram doses, and the systematic review of the indication people buy it for is negative and a quarter of a century old.
And here is the obstacle, and it is arithmetic rather than biology. The myoclonus trial used 2.4 to 16.8 g/day. A partner sells this as 800 mg and 1200 mg tablets. One 1200 mg tablet is half the bottom of the only dose range with a convincing controlled result, and a fifteenth of the top of it. Before anybody argues about whether piracetam works, the dose being compared has to be stated — and in community practice it usually is not.
Piracetam pharmacokinetics — how much of it actually gets in
Say the honest thing first: there is no US label for this drug to read. Piracetam has never been approved in the United States, so DailyMed carries no prescribing information for it, and the half-life figure of roughly five hours that circulates for it traces to European product information rather than to anything this page can put a resolvable identifier on. Treat the number as second-hand. What follows is the reasoning that bounds it, which is checkable.
What degrades it: essentially nothing, and that is the unusual part. Piracetam is a small, neutral, extremely water-soluble 2-oxopyrrolidine acetamide. It has no ester for gut esterases, no peptide bond for brush-border peptidases and no obvious soft spot for cytochrome-mediated aromatic hydroxylation, because it has no aromatic ring at all. The one hydrolysable feature is the primary amide. Its descendant, which shares that feature and adds an ethyl group, is described on its own label as not extensively metabolized, with the major pathway being enzymatic hydrolysis of the acetamide group producing a carboxylic acid metabolite at 24% of dose, not dependent on any liver cytochrome P450 isoenzyme Keppra label 2026. That is the best-anchored statement available about what happens to this chemistry in a person, and it is labeled here as an extrapolation from the descendant, not as a measurement of the parent.
The oral barrier: there isn't one, and the same label gives the numbers. Levetiracetam's oral bioavailability is 100%, peak plasma concentrations arrive in about an hour, plasma protein binding is less than 10%, plasma half-life is 7 ± 1 hour, and 66% of an administered dose is eliminated unchanged by renal excretion Keppra label 2026. Every one of those properties follows from being small, neutral and hydrophilic, and piracetam is smaller and more hydrophilic still. The practical consequences are three: the drug is cleared by the kidney rather than the liver, so reduced kidney function raises exposure and cystatin C is the relevant measurement; there is no meaningful cytochrome interaction to worry about; and the gram-scale dosing in the myoclonus literature is not a delivery workaround but the actual potency of the molecule.
Why nobody injects it, and what that implies. Parenteral piracetam has existed in European practice as an intravenous preparation, but for a compound with complete oral absorption an injection changes only the shape of the first hour. Contrast that with the peptides on this site, where injection exists because the oral route destroys the molecule. Here the route is not the constraint. The constraint is that a five-hour half-life at gram doses means three-times-daily dosing to hold a level, which is how the drug is used clinically for myoclonus and is not how it is used by anybody taking one tablet with breakfast.
What would have to be true, and how you would know it was not
Four predictions. The first is the mechanism's own, and it argues against the way the compound is sold.
1. Against the product: in a healthy adult, a cognitive screen will not move. Muller 1999 states that the effect is always much more pronounced when function is impaired, and Flicker 2001 could not support the cognition indication even in impaired populations. So: MoCA and trail making, part B, at baseline and after eight weeks. Prediction: no change beyond test-retest noise. A page that predicted improvement here would be contradicting the only mechanistic argument the compound has.
2. The dose being used is a tenth of the dose that worked, and that is testable before anything else. The one convincing controlled result used 2.4 to 16.8 g/day Brown 1993. Anyone evaluating this compound at 800 to 1600 mg is testing a different exposure, and the honest prediction is that whatever they conclude is uninformative about the drug. This is the cheapest correction on the page and almost nobody applies it.
3. The hematologic claim has a marker and nobody has drawn it. The membrane argument predicts improved erythrocyte deformability and normalized platelet aggregation Muller 1999. The accessible read-outs are a CBC with indices and fibrinogen, at baseline and at 12 weeks of gram-scale use. No published series reports either around a piracetam course in a healthy adult. If the effect is real it should be measurable in the most ordinary blood tube there is.
4. Kidney function should predict who feels anything. If this chemistry is cleared unchanged by the kidney, as its descendant is at 66% of dose Keppra label 2026, then exposure at a fixed milligram dose scales inversely with filtration. Cystatin C with an estimated glomerular filtration rate is the measurement. Prediction: at the same dose, people with lower filtration report more effect and more side effects. Nobody has stratified a piracetam observation this way, and it is the most likely explanation for the enormous person-to-person variability the community reports.
What nobody has tested yet
The single experiment that would settle the mechanism has never been published. Run piracetam against the SV2A binding assay that identified levetiracetam's target Keppra label 2026 Contreras-Garcia 2022, at the concentrations a gram-scale oral dose actually produces. It is an off-the-shelf radioligand displacement experiment. Either the parent shares its descendant's target at achievable concentrations, which would rewrite every page about this class, or it does not, which would close a sixty-year-old question. Nobody has reported it either way.
The Cochrane review has not been updated since 2001. Flicker 2001 is the reference everybody cites for the negative verdict on cognition, and it is a quarter of a century old. Trials have been published since; imaging endpoints exist that did not; the dose question above has never been addressed by a review. Whatever the answer, a page that leans on a 2001 systematic review should say out loud how old it is.
Nobody has published what is in the tablets on this shelf. Vanhee 2025 is the closest available: 12 official medicines control laboratories, 159 samples across Europe and Australia between January 2020 and September 2024, 34 distinct molecules identified, 69% collected from the illegal market, with prescription-only Russian medicines found in pharmacological quantities and noopept, phenylpiracetam and phenibut intercepted as bulk raw material. Piracetam sits in exactly that supply chain. No assay of the specific products a reader can order has been published.
Extrapolation, labeled as such. If the membrane-fluidity account is right, three things follow that nobody has looked for. The effect should be absent in young healthy membranes and present in aged ones from the same donor, which is a single comparative assay. It should show no stereoselectivity, because a lipid head group is not a chiral binding pocket — and stereoselectivity is precisely what identified SV2A for the descendant Keppra label 2026. And it should be shared by other small neutral amides of similar polarity, which would make piracetam unremarkable rather than special. Each is an ordinary biophysics experiment and none appears in the published record.
Piracetam — its own safety story, not its class's
Three things specific to this compound rather than to its class.
The kidney is the exit, so the kidney is the risk. This chemistry leaves the body largely unchanged in urine — 66% of dose for the descendant that has been measured Keppra label 2026 — which means reduced filtration raises exposure at any fixed dose. At the gram-scale doses the myoclonus literature uses Brown 1993 that is not a theoretical concern. Anyone with known kidney impairment is taking a larger effective dose than the label on the bottle implies, and cystatin C with an estimated filtration rate is the measurement that says by how much.
What zero means here, said precisely. There is no US prescribing information for piracetam, so there is no regulator-reviewed adverse-event table to quote — not a clean safety record, an absent one. The best-documented human exposure is a 21-patient crossover in a neurological population on concurrent antimyoclonic drugs Brown 1993, which is far too small to detect anything uncommon. The reassurance people take from decades of European use is real but it is pharmacovigilance, not a trial database.
The supply chain is the live risk and it is documented. Vanhee 2025 found that most nootropic samples seized or sampled by twelve national control laboratories came from the illegal market, that prescription drugs turned up in them in pharmacological quantities, and that consumers buying products presented as dietary supplements may not know what they contain. For a compound whose own pharmacology is mild, the largest single hazard on this page is not the molecule. It is what else is in the tablet, and nobody has measured that for the specific products a reader can order.
Sources read for this page
- Muller WE, Eckert GP, Eckert A. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry 1999 · PMID 10338102
- Leuner K, Kurz C, Guidetti G, Orgogozo JM, Muller WE. Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam. Frontiers in Neuroscience 2010 · PMID 20877425
- Brown P, Steiger MJ, Thompson PD, Rothwell JC, Day BL, Salama M, Waegemans T, Marsden CD. Effectiveness of piracetam in cortical myoclonus. Movement Disorders 1993 · PMID 8419809
- Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews 2001;(2):CD001011 · PMID 11405971
- Contreras-Garcia IJ. Levetiracetam Mechanisms of Action: From Molecules to Systems. Pharmaceuticals (Basel) 2022 · PMID 35455472
- U.S. Food and Drug Administration. KEPPRA (levetiracetam) tablets and oral solution - full prescribing information, including the SV2A binding-site statement and the pharmacokinetics section. DailyMed, U.S. National Library of Medicine; UCB Inc. label version 36, revised January 2026
- Vanhee C, Deconinck E, George M, Hansen A, Hackl A, Wollein U, El-Atma O, Beerbaum N, Aureli F, Borioni A, et al. The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories. Journal of Xenobiotics 2025;15(3):88 · PMID 40558871
Piracetam — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Piracetam — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Piracetam moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Piracetam in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Piracetam
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Piracetam — frequently asked questions
What is Piracetam?
Piracetam (Nootropil, Memotropil, Pirasmart — the 1964 parent of the racetam class) is a cognitive & mood research compound. The molecule every other racetam on this site is a derivative of, and the one with no identified receptor after sixty years. The mechanism on offer is physico-chemical rather than pharmacological: an interaction with the polar head groups of the phospholipid bilayer that alters membrane fluidity, reported as larger in aged brain membranes than young ones, with a mitochondrial extension — raised membrane potential and ATP production — proposed on top of it. Its own structural descendant, levetiracetam, does have a named target: the synaptic vesicle protein SV2A.
Where can I find Piracetam dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Piracetam protocol are available to members inside Skool. This public page covers what Piracetam is, how it works and the evidence.
What is the half-life of Piracetam?
Piracetam has an approximate half-life of ~5 hrs (European product information; there is no US label), which is part of what determines how often it's dosed.
What's the evidence behind Piracetam?
Current evidence level: Human trials — positive in cortical myoclonus; the Cochrane review for dementia and cognitive impairment does not support that use. Not approved in the US.. Piracetam is offered for research purposes only and is not an approved medicine.
What Piracetam is used for
Piracetam appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.